Important Updates on COVID-19

As the COVID-19 (coronavirus) pandemic continues to evolve around the world, Otsuka stands united with our global community to navigate this fast moving and complex healthcare event.

Read the full statement
  • Kabir Nath

    M.A., MBA
    President & CEO, Otsuka North America Pharmaceutical Business

    Kabir Nath

    M.A., MBA
    President & CEO, Otsuka North America Pharmaceutical Business

    "Otsuka is dedicated to developing breakthrough therapies and contributing to the future of medicine. As a company, we don’t just follow the crowd or look to established processes for answers. We persevere, trying new avenues until we reach our goals. In all of our activities, we’re driven by a commitment to creating new products for better health worldwide. Our employees are at the helm of this mission and the patients we humbly serve are at the core. We are honored to devote our corporate lives to helping others."

    Kabir has nearly thirty years of broad international biopharmaceutical and medical device experience. He has shaped strategy and delivered results in complex, challenging business environments at country, regional, and global levels. Kabir joined Otsuka in March 2016 to head all commercial operations within our North American pharmaceutical businesses. In March 2018 he was appointed to the board of Otsuka Pharmaceutical Company (“OPC”), with responsibility for North America. In March 2020, Kabir was appointed Senior Managing Director, Global Pharmaceutical Business, OPC, with overall operational leadership for the global pharma business, overseeing the regions of North America, Europe, Japan, and the rest of Asia. Kabir’s responsibilities include brand strategy, sales and marketing, clinical development and business development. He continues to oversee the North American business in parallel. Before joining Otsuka, Kabir spent 13 years in senior leadership roles at Bristol Myers Squibb (BMS), including Vice President for South East Asia/Taiwan/Hong Kong, President of BMS China and President, Asia Pacific Medicines, overseeing all commercial operations in 13 countries. He subsequently spent several years in roles of increasing responsibility within specialty franchises of BMS (Immunoscience, Virology and Neuroscience), in both Global Commercialization and US operations.  Prior to joining BMS, Kabir spent 11 years at the medical technology company Smith and Nephew in senior operational and strategic roles in the United Kingdom, Europe, and Asia. He has lived and worked in the United Kingdom, France, Spain, India, Singapore, China, and the United States. Kabir holds an MA from King’s College, University of Cambridge, and an MBA with Distinction from INSEAD.
  • Karen Gally

    J.D.
    VP & General Counsel, Legal Affairs

    Karen Gally

    J.D.
    VP & General Counsel, Legal Affairs

    As Vice President & General Counsel, Karen focuses on the legal issues of clinical development, product commercialization, and corporate governance. Karen has the privilege to support pharmaceutical compounds from "cradle to grave", from early clinical development through loss of exclusivity and beyond. Karen's work primarily focuses on the Otsuka compounds used to treat serious mental illness including schizophrenia, major depression, bipolar I disorder, and Alzheimer's disease; she has also worked in the areas of oncology, neurology, and renal disease. Karen's work also involves supporting the Boards of Directors of OPDC and its sister company, Otsuka America Pharmaceutical, Inc. (OAPI); she is also Corporate Secretary of Neurovance, an Australian subsidiary of OAPI. Prior to joining Otsuka in 2003, Karen was an Associate with Epstein, Becker & Green in the Washington, D.C., office in the national health law practice group. From 1996 through 2003, she represented national healthcare companies in the areas of durable medical equipment, home healthcare, and pharmaceuticals in criminal and civil investigations. Before attending law school, Karen worked in public relations and public policy for a division of Beth Israel Medical Center in New York City, and for the New York State Conference of Blue Cross and Blue Shield Plans in Albany. Karen earned her J.D. from the University of Maryland Law School in Baltimore, and a Bachelor of Arts from Dartmouth College in Hanover, New Hampshire.
  • Christoph Koenen

    M.D., MBA
    EVP & Chief Medical Officer

    Christoph Koenen

    M.D., MBA
    EVP & Chief Medical Officer

    "We encourage people in the R&D organization to think differently. Creativity and perseverance are two important capabilities to drive innovation. Our innovations and our way of working help to achieve better health worldwide."

    As Executive Vice President and Chief Medical Officer of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Christoph helps define the global R&D strategy and has direct responsibility for taking all compounds for global registration from first in human through to regulatory approval. As a seasoned clinical development leader, Christoph works collaboratively across the leadership team to help refine the clinical development strategy and roadmap for implementation. In addition, Christoph has oversight of clinical management to ensure studies are completed on time and within budget. Christoph continues to invest in new and innovative means of conducting clinical trials as well as other innovative ways of data collection. Christoph's responsibilities include Medical Affairs which consists of medical strategy and field medical. Christoph and the Medical Affairs team are the bridge between the research and commercial organizations. Before joining Otsuka in 2019, Christoph was Head of Cardiovascular Medicine and Development at Bristol-Meyers Squibb (BMS). In this role Christoph helped BMS to develop its next generation of cardiovascular medicines. Christoph was also responsible for ongoing data generation for Eliquis (one of the most successful drugs in the industry) and was a catalyst behind the creation of the largest Real World Evidence data generation initiative created in the field of anticoagulation. Prior to joining BMS in 2011, Christoph worked for Novo Nordisk in various medical and development functions in Europe, as well as in the US. Christoph's dual medicine-business background has informed his ability to combine scientific innovation with a strategic approach to business development opportunities, regulatory navigation, and global patient access solutions. Christoph received his medical degree from Ruprecht-Karls University School of Medicine in Heidelberg, Germany, in 1994. He also holds an MBA from Schiller International University. Christoph is board certified in internal medicine and diabetology.
  • Nick Kurahashi

    M.S.
    VP, Global CNS Business

    Nick Kurahashi

    M.S.
    VP, Global CNS Business

    Nick is Vice President of the Global CNS Business for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). He is responsible for alliance management with companies that Otsuka has alliances with, as well as development of global clinical and commercialization strategy for central nervous system (CNS) and digital innovation products. His career at Otsuka began in 1988 as a researcher and organic chemist for psychiatric disorders in the CNS group in Japan and has steadily progressed to the clinical and commercial aspects of the pharmaceutical business, as well as taking on global roles. In 1996, he became the Product Development Coordinator responsible for the development and coordination of the global clinical and commercialization plan for an anti-platelet agent. Starting in 2000, he was the International Manager of ABILIFY (aripiprazole) at Otsuka America Pharmaceutical, Inc (OAPI). He managed coordination between the U.S., E.U., Japan, and Asia, as well as allied companies. By 2003, he became the ABILIFY Product Marketing Manager, leading the brand in Japan, until beginning his current role in 2010. Nick had the unique opportunity and honor of contributing to the research and development and commercialization of ABILIFY. During his tenure at Otsuka, global mobility afforded him an opportunity to exchange knowledge with peers, bringing different perspectives and problem-solving abilities to the conversation based on professional backgrounds. Today, he is passionate about the future of Otsuka and how the company can leverage technology and digital innovation to advance healthcare and help make the world a healthier place for all. Prior to joining Otsuka, Nick received a Master of Science in pharmacy from Gifu Pharmaceutical University.
  • Angela Colon-Mahoney

    M.S.
    VP, People and Business Services

    Angela Colon-Mahoney

    M.S.
    VP, People and Business Services

    As VP of People and Business Services, Angela leads the Human Resources function, Language Services, and the Information Resource Center for Otsuka in the U.S. and serves as a member of Otsuka's Executive Leadership Team. Angela is helping Otsuka transition to an integrated U.S. business on the Road to 2030 with a strategic focus on succession planning, organization design, and advanced human capital practices. Angela's areas of focus include building capabilities in people analytics, streamlining HR systems, business partner consultancy, talent and leadership development, change management, and organizational effectiveness. Angela also oversees Otsuka's Total Rewards program, HRIS, HR Enablement and Recruitment. She also oversees the development of the North America ReadyNOW team of sales personnel with the goal of developing a unique sales profile to accelerate the core commercial business and enable a long-term multi-product strategy for CNS, Nephrology, and Digital Medicine. Before joining Otsuka in 2018, Angela served in a variety of senior roles leading human resources and transformations in global companies across multiple industries. Angela was the HR Leader at The Estée Lauder Companies, where she led global shared service and technology transformations while working with the CEO and C-suite officers around the globe. Prior to Estée Lauder, Angela was Global Talent and HR Leader for Tyco, where she led the enterprise's talent management strategy and global performance management processes and systems. Angela has also served as an Organization Development Consultant for Mercer Consulting. She has built global centers of expertise in talent acquisition, talent management, learning and development, total rewards, and HR communications. Angela has a Bachelor of Arts in Psychology from St. John's University and a Master of Science in Organization Change Management from The New School University.
  • Jennifer McGee

    J.D.
    VP, Ethics & Compliance, Global Chief Compliance Officer

    Jennifer McGee

    J.D.
    VP, Ethics & Compliance, Global Chief Compliance Officer

    “I really enjoy working with our various business functions to help them deliver on Otsuka’s promise, while keeping integrity at the center of everything we do. I firmly believe that when we harness our collective ability, passion, and experience, we empower our teams to defy limitation, so that others can too.”

    As VP, Ethics & Compliance and Global Chief Compliance Officer, Jennifer ensures that Otsuka maintains its commitment to a culture of integrity through its comprehensive Ethics and Compliance Program, which includes communications, training, risk assessment, auditing and monitoring, and internal investigations.   She also oversees Corporate Affairs which includes Government Affairs, Corporate Communications, and Patient Advocacy & Stakeholder Management. Jennifer joined Otsuka in January 2011 as Senior Compliance Counsel and assumed the responsibilities of Chief Compliance Officer in May 2015. Prior to joining Otsuka, she worked as a litigator at a multinational law firm, focusing on defending pharmaceutical and medical device manufacturers in government investigations and lawsuits. She also served on active duty in the US Army for more than 13 years, trying more than 70 felony criminal trials. Jennifer then served in the US Army Reserve for an additional 13 years, retiring in 2017. Jennifer earned her bachelor’s degree from St. Lawrence University and her JD from the University of Maryland School of Law.
  • Robert McQuade
    Robert McQuade

    Ph.D.
    EVP & Chief Strategy Officer

    Robert McQuade

    Robert McQuade

    Ph.D.
    EVP & Chief Strategy Officer

    Otsuka is not right for everyone. It is a dynamic environment for those who wish to be challenged and engaged every day. We are focused on bringing important new drugs and innovations to patients, especially for those with serious mental illness. This has been my personal goal throughout my career and through Otsuka I believe that I have in fact made a difference in the lives of these patients.

    As Executive Vice President and Chief Strategy Officer at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Robert is responsible for coordinating the development strategy for Otsuka's compounds across their life cycles. He has more than 30 years of experience in the discovery, development, and marketing of drugs for the treatment of mental illness. Robert's career started as a post-doctoral fellow in central nervous system (CNS) research at Schering-Plough and gradually advanced to Associate Director of CNS Pharmacology. In this role, he supervised the biochemical pharmacology group in their efforts to discover new drugs for mental illness, including schizophrenia and Alzheimer's disease. Robert next joined Global Medical Affairs at Bristol-Myers Squibb (BMS). While at BMS, he was responsible for various products, including psychiatric treatments for generalized anxiety disorder and major depressive disorder. More importantly, he was part of the team that helped form the alliance between BMS and Otsuka for the development and commercialization of ABILIFY (aripiprazole). It was only natural that Robert ultimately joined Otsuka in 2004 to oversee global medical affairs for ABILIFY. His roles have grown over the years, and now he is responsible for the global development strategy for Otsuka's compounds in the CNS, cardio-renal, and oncology therapeutic areas. In addition, he is involved in many of Otsuka's external collaborations and business development initiatives. Robert received a Bachelor of Science from Davidson College and a Ph.D. from the University of North Carolina, Chapel Hill.
  • Innes Meldrum

    SVP & Chief Commercial Officer

    Innes Meldrum

    SVP & Chief Commercial Officer

    “Otsuka is a place where you’re actively encouraged to be yourself and not conform to the status quo. This unique working environment has a strong focus on ensuring an authentic, people focused culture that encourages individual growth via the generation of new ideas and supports taking on increased responsibility allowing progressively greater contribution to the success of our business.”

    As Senior Vice President & Chief Commercial Officer, Innes is responsible for the commercial success of the North American business which includes Neuroscience, Nephrology and Digital products. In addition, Innes oversees Commercial Strategy and Commercial Operations including Market Access, Training and Development, Sales and Marketing Operations, as well as Business Insights and Strategy. Innes joined Otsuka in 2017, with more than 20 years of executive experience successfully leading commercial teams in the Pharma and Technology industries at both the global and local level. Prior to Otsuka, he spent three years at Orexo as Head of US Sales and Marketing, focused on the opioid addiction market. Before his role at Orexo, Innes worked in a variety of global and US roles at Novartis and, most recently, was Head of Sales and Marketing of the US Neuropsychiatry business. Prior to joining Novartis, he spent 10 years working in the technology industry with Nortel Networks, HP, and Agilent Technologies, focused on developing solutions for the wireless telecoms industry. Innes earned his B.Eng. in electrical and electronic engineering from the University of Strathclyde in Glasgow, Scotland.
  • Edward Stelmakh
    Edward Stelmakh

    MBA
    SVP, Chief Operating Officer & Chief Financial Officer

    Edward Stelmakh

    Edward Stelmakh

    MBA
    SVP, Chief Operating Officer & Chief Financial Officer

    “My journey at Otsuka has been a continuous evolution that spans many parts of the enterprise and continuously pulls on a diverse skillset that fits with my own philosophy on work. Otsuka’s amalgamation of a strong desire to make a difference in the world, combined with providing its people with an endless range of possibilities to learn and grow, is embedded in its cultural tenets and makes this organization a truly unique place to work. This is a company that seizes the opportunity to take the uncharted path towards the future by doing what “only Otsuka” can do, while staying firmly rooted in its rich one hundred year history and embracing those that are willing to join that journey.”

    As Senior Vice President, COO and CFO, Ed is responsible for all areas of Channel Strategy & Patient Support, Data & Analytics, Finance, Information Technology, Technical Operations and Business Services.  Prior to joining Otsuka in 2015, Ed served six years as Vice President, Finance, Clinical Development and Commercialization Services at Covance (a division of LabCorp), leading the finance and commercial support functions of a global billion-dollar division with 5,000 employees worldwide. Prior to Covance, he held a variety of positions within Johnson & Johnson, Sanofi-Aventis, Organon/Schering-Plough and Mylan. His background includes a broad spectrum of financial, commercial, partnership/alliance governance, and operational leadership roles, including eight years of international assignments in the Netherlands and Russia. Ed received his BA in finance from Towson University and his MBA from the University of Baltimore. He is also a Certified Public Accountant (inactive) and a Certified Management Accountant.  Ed serves as Treasurer and on the Executive Committee of the Board of Directors of the American Foundation of Suicide Prevention, a national organization dedicated to saving lives and bringing hope to those affected by suicide. He is also an active member of the Princeton community and serves on the Board of the Arts Council of Princeton.

NEUROSCIENCE

Otsuka has been committed for more than 3 decades to developing novel drugs for neurological conditions.